Experiences, learnings and perspectives in the regulation of agricultural biotechnology: the view from Argentina.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-06-06 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1600642

Dalia M Lewi, Perla Godoy, Facundo Simeone

引用次数: 0

Abstract

Argentina has established itself as global leader in setting enabling regulations for agricultural biotechnology. Between 2020 and 2023 the responsible administration strengthened this position through the adoption of innovative regulations for New Breeding Techniques and fostering broad international collaboration. The experience accumulated during this period serves to illustrate best practices, current shortcomings, anticipate future challenges, and point to the solutions that the sector will need in the next few years.

查看原文本刊更多论文

农业生物技术管理的经验、教训和观点：来自阿根廷的观点。

阿根廷在为农业生物技术制定有利法规方面已经确立了自己的全球领导地位。在2020年至2023年期间，负责任的行政部门通过采用创新的新育种技术法规和促进广泛的国际合作，加强了这一地位。在此期间积累的经验有助于说明最佳做法，当前的缺点，预测未来的挑战，并指出该行业在未来几年内需要的解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.